Article in Biomolecules, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
4 citing papers in PubMed, 19 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors at 4 institutions in 2 countries.
Vittorio CanaleDepartment of Organic Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna Street, 30-688 Krakow, Poland.ORCID 0000-0001-7940-9500
Wojciech TrybałaDepartment of Organic Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna Street, 30-688 Krakow, Poland.
Séverine Chaumont-DubelInstitut de Génomique Fonctionelle, Université de Montpellier, CNRS, INSERM, 34094 Montpellier, France.ORCID 0000-0001-6860-6891
Paulina Koczurkiewicz-AdamczykDepartment of Pharmaceutical Biochemisty, Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna Street, 30-688 Krakow, Poland.ORCID 0000-0003-2939-224X
Grzegorz SatałaDepartment of Medicinal Chemistry, Maj Institute of Pharmacology, Polish Academy of Sciences, 12 Smętna Street, 31-343 Krakow, Poland.
Ophélie BentoInstitut de Génomique Fonctionelle, Université de Montpellier, CNRS, INSERM, 34094 Montpellier, France.
Klaudia Blicharz-FuteraDepartment of Organic Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna Street, 30-688 Krakow, Poland.
Elżbieta PękalaDepartment of Pharmaceutical Biochemisty, Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna Street, 30-688 Krakow, Poland.ORCID 0000-0002-1260-4253
Andrzej J BojarskiDepartment of Medicinal Chemistry, Maj Institute of Pharmacology, Polish Academy of Sciences, 12 Smętna Street, 31-343 Krakow, Poland.ORCID 0000-0003-1417-6333
Frédéric LamatyIBMM, Université de Montpellier, CNRS, ENSCM, 34095 Montpellier, France.
Philippe MarinInstitut de Génomique Fonctionelle, Université de Montpellier, CNRS, INSERM, 34094 Montpellier, France.ORCID 0000-0002-5977-7274
Paweł ZajdelDepartment of Organic Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna Street, 30-688 Krakow, Poland.ORCID 0000-0002-6192-8721
Jagiellonian University · PLÉcole Nationale Supérieure de Chimie de Montpellier · FRCentre National de la Recherche Scientifique · FRMaj Institute of Pharmacology · PL
Funding
Agence Nationale de la Recherche ANR-16-IDEX-0006National Science Center DEC-2021/05/X/NZ7/01847
6 · The paper itself
Abstract
In addition to the canonical Gs adenylyl cyclase pathway, the serotonin type 6 receptor (5-HT
Indexed as
Drug Inverse AgonismSerotoninCognitionLigandsPiperazinesLigandsPiperazinesSerotonin5-HT6 receptor inverse agonism/neutral antagonismglioprotective propertiesGs and Cdk5 signaling pathwaysmechanochemical synthesisrotenone toxicity
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
1-(Arylsulfonyl-isoindol-2-yl)piperazines as 5-HT · full record | OpenQuestion